Predicted protein targets (top 3)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EGFR | P00533 | 1/20 | 0.32 |
| ▸ | ERBB2 | P04626 | 1/20 | 0.32 |
| ▸ | RET | P07949 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL26122121 | 1.00 | EGFR (0.32) | EGFRERBB2RET | |
| SCHEMBL30556857 | 1.00 | EGFR (0.32) | EGFRERBB2RET | |
| SCHEMBL2927453 | 0.78 | GAA (0.32) | EGFRERBB2 | |
| SCHEMBL2927456 | 0.78 | GAA (0.32) | EGFRERBB2 | |
| SCHEMBL19656322 | 0.78 | — | — | |
| SCHEMBL17573082 | 0.72 | CCNC (0.32) | — | |
| SCHEMBL31749682 | 0.61 | MAPK1 (0.40) | — | |
| SCHEMBL16013200 | 0.61 | EGFR (0.36) | EGFRERBB2 | |
| SCHEMBL16013981 | 0.61 | EGFR (0.36) | EGFRERBB2 | |
| SCHEMBL2416474 | 0.60 | APLNR (0.30) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11213520-B2 | Phenylpyrazolylacetamide compounds and derivatives as CDK8/CDK19 inhibitors | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2022-01-04 | — | — | US | disclosed |
| EP-3464267-B1 | NEW PHENYLPYRAZOLYLACETAMIDE COMPOUNDS AND DERIVATIVES AS CDK8/CDK19 INHIBITORS | BOEHRINGER INGELHEIM INT (DE) | 2020-09-23 | — | — | EP | disclosed |
| US-20190290637-A1 | NEW PHENYLPYRAZOLYLACETAMIDE COMPOUNDS AND DERIVATIVES AS CDK8/CDK19 INHIBITORS | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2019-09-26 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11213520-B2 | Phenylpyrazolylacetamide compounds and derivatives as CDK8/CDK19 inhibitors | CDK9, CDK19, CDK8 | EGFR 1107/4885ERBB2 593/4885RET 1307/4885 |
| US-20190290637-A1 | NEW PHENYLPYRAZOLYLACETAMIDE COMPOUNDS AND DERIVATIVES AS CDK8/CDK19 INHIBITORS | CDK9, CDK19, CDK8 | EGFR 1277/4885ERBB2 635/4885RET 1427/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.